A*STAR Joins Forces with Swiss Company, Cytos, to Combat HFMD

摘要

A*STAR's Singapore Immunology Network (SIgN) and Swiss company Cytos Biotechnology Ltd (Cytos) have pledged to work together to develop fully human monoclonal antibodies for combating and managing the Enterovirus 71 (EV71), one of the two most commonviruses responsible for hand, foot and mouth disease (HFMD) in Singapore. This collaborative research is especially timely for Singapore, which has seen seasonal outbreaks of this highly infectious disease that largely afflicts young children. There is currently no specific treatment available for HFMD.